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Abstract:  Embryonic midbrain micromass cultures were exposed for five days to 
ochratoxin A (OTA) at seven concentrations (ranging from 0.16 to 10 µg/mL). Cell 
viability was assessed in neutral red uptake test (NRU), and differentiation – by 
immunoenzymatic determination of structural proteins (βIII-tubulin, MAP2, GFAP) 
expression level as well as by computer image analysis. Dose dependent decrease in cell 
number and differentiation was observed. Concentration-response curves were analysed 
and the mean inhibition concentrations (µg/mL) for cytotoxicity (IC50) and differentiation 
(ID50) were calculated. There were no significant differences in the sensitivity of neurons 
in early and late stage of differentiation and astrocytes to the toxic activity of this 
compound. For all endpoints ID50 value was very low (< 10 µg/mL) so OTA was 
classified as a strong teratogen. IC50/ ID50 ratios <2 pointed out that with harmful action 
of OTA the basic cytotoxicity should be connected. 
 
Keywords:  Ochratoxin A; developmental neurotoxicity; in vitro micromass cultures; 
embryonic midbrain cells; computer image analysis; immunocytochemistry. 
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1. Introduction  
 
The developing central nervous system (CNS) is much more vulnerable to injury from toxic agents 
than the adult CNS. In fact, if we consider congenital defects, we see the brain as the major target of 
toxicity [1]. Moreover, CNS effects are seen most often at lower doses than those required to affect 
other parts of the body. Because of growing recognition of apparent increase in the incidence of 
developmental disabilities, considerable attention is focused on the effects of exposures to 
environmental pollutants such as methylmercury, lead, arsenic, polychlorinated biphenyls (PCBs), 
dioxins, and pesticides [2, 3]. Studies of food contaminants are of great importance [4]. 
Ochratoxin A (OTA) is a mycotoxin that occurs in improperly stored food products and is produced 
by some Aspergillus and Penicillium species. It primarily disrupts renal function and has been 
discussed as a causative factor in the human disease “Balkan endemic nephropathy” (BEN) and in the 
development of urinary tract tumours in humans [5]. OTA is also known to cause a wide range of other 
toxic effects, including carcinogenicity, hepatotoxicity, neurotoxicity, and teratogenicity [6, 7] as well 
as immunomodulating and often immunosuppressive action [8, 9].  
Most of the available data on teratogenicity (developmental toxicity) of OTA comes from rodent 
studies in which developmental neurotoxicity was indicated by both morphological or behavioural 
changes. Pregnant golden hamsters injected i.p. once with 2.5-20 mg OTA/kg b.w. between 7-10 days 
of gestation increased prenatal mortality and on day 9 diminished foetal growth and malformations 
such as micrognathia, hydrocephaly, short tail, oligodactyly, syndactyly, cleft lip, micromelia, and 
heart defects occurred [10]. Embryocidal, foetotoxic and teratogenic effects of OTA were found in rats 
after a single s.c. dose of 1.75 mg/kg between days 4-10 of gestation [11, 12]. OTA at different graded 
dose levels (2-4 mg/kg body weight) and different gestation days (6-15), caused variable 
developmental defects (external hydrocephaly, incomplete closure of skull, and omphalocele) in 
foetuses [13]. A single oral dose of 2.75 mg/kg b.w. was found as the minimum effective teratogenic 
dose. Craniofacial malformations included exencephaly, midfacial clefting, and cleft lip were found in 
mice exposed to OTA [14]. Mice pups exposed prenatally to OTA were examined in surface righting 
(days 3-12), swimming, and pivoting tests [15]. Statistically significant differences for all three tests 
indicated that developmental delay had occurred; however no treatment or dose–related pathoanatomic 
alterations were found. The examination of brain regions of three month mice offspring exposed 
prenatally to OTA revealed that both, tissue weight and DNA content were reduced to 80% of control 
in cerebral hemispheres and 90% in remainder of the brain [16]. It was found that microcephalic brains 
in mice exposed to OTA were resulted from a reduced dendritic growth [17]. The treatment of 
postimplantation rat embryos in culture resulted in both concentration - dependent reduction in yolk 
sac diameter, crown-rump length, somite number count, and protein and DNA content  as well as in an 
increase in the incidence of defective embryos (hypoplasia of telencephalon) [18].  
Up to the present, the mechanism of toxic action of OTA on the prenatal development of the central 
nervous system has not been fully characterised. New in vitro strategies based on cell cultures are 
promising; however, the complexity of the nervous system requires the use of various cellular models 
representing specific in vivo targets [19 - 22]. The aim of this study was to gain more insight into the 
influence of OTA on the embryonic neural cells cultured in high density “micromass cultures”.  
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2. Materials and Methods 
 
2.1. Animals — donors of embryonic midbrain cells 
 
This study was carried out according to compliance with bioethical principles. Wistar albino rats 
were housed under standard laboratory condition of lighting (12 h dark/12 h light), temperature (20 ± 2 
°C), and relative humidity (50 – 60%) with free access to commercial feed (Murigan) and tap water. 
Animals (10-12 week old) were mated overnight and the appearance of a vaginal plug on the next 
morning was considered as day one of pregnancy. Rat embryos were collected on day 13 of gestation. 
Procedures were followed essentially as described in INVITTOX Protocol No. 114 [23]. 
Tissues were pooled from a number of embryos, washed and incubated for 20 min at 37 ºC in 
sequence in Earle’s balanced salt solution calcium and magnesium-free (CMF, GIBCO), and 1% 
trypsin (GIBCO) in CMF. Then the tissues were washed in CMF and culture medium (Ham’s F-12 
nutrient mixture: foetal bovine serum: L-glutamine: penicillin/streptomycin - 88:10:1:1 v/v – all 
materials were from GIBCO). A single cell suspension was ensured by mechanical dissociation 
followed by passing the suspension through sterile 10  μm nylon mesh. Viable cells density was 
assessed by trypan blue exclusion assay using Bürker’s haemocytometer.  
 
2.2. Compounds tested 
 
An ochratoxin A (OTA) analytical standard was purchased from SIGMA. Stock solutions of this 
compound were prepared by dissolving it in ethanol, whereas working dilutions (0.16 – 10.0 μg/mL) 
were prepared in culture medium. Penicillin G sodium salt (Pen-G, SIGMA) served as negative control 
and 5-fluorouracil (5-FU, SIGMA) as the positive one. Control plates included 5-FU at concentrations 
ranged from 0.015 to 1.0 μg/mL and Pen-G at the concentration of 500 μg/mL. Working dilutions of 
both control compounds were prepared in medium. 
 
2.3. Embryonic nerve cell cultures 
 
High-cell-density cultures were set up carefully as a 5-10 μL drop in the centre of each well of 96-
well fibronectin coated microplate (BECTON DICKINSON), so that number of cells /well was 5 × 
10
4. After 2 h incubation (37
oC, 5% CO2) the cells were exposed to different concentrations of tested 
compounds and incubated five days. Then dual assessment i.e. cytotoxicity and an impact of tested 
compound on cells differentiation (embryotoxicity) were done in the same cultures. 
 
2.4. Cytotoxicity assay 
 
Cytotoxicity was quantified using neutral red uptake test (NRU). The cells were fixed with 4.5% 
glutaraldehyd solution (SIGMA) for 30 min at room temperature and then washed with 
0.9% phosphate buffered saline (PBS, SIGMA). After 30 min (room temperature) staining with 0.05% 
neutral red (SIGMA), acid alcohol (1% acetic acid in 50% ethanol) was added to extract neutral red Int. J. Mol. Sci. 2009, 10                 
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from living cells. The eluted stain intensity (optical density, OD) was measured at 540 nm following at 
least 2 h incubation. Surviving cell number was directly related to the absorbance of the eluted stain.  
 
2.5. Assessment of differentiation 
 
2.5.1. Computerised image analysis 
 
After removing the eluted solution, the cells were fixed in 10% formaldehyde for 20  min and 
stained (approximately 10  s) with Gill’s haematoxylin. Morphometric analysis was performed on 
digitised images of cells taken with Nikon SMZ stereoscopic microscope linked to Panasonic CCD 
BP-KR 222E colour camera. The number of neurospheres (containing differentiated neural cells) was 
counted and their total and individual area was measured using computer image analysis software 
(LUCIA Measurement System).  
  
2.5.2. Immunostaining 
 
To indicate the target cells damaged, immunofluorescent (IF) and immunoenzymatic (IE) staining 
was performed. Cells were fixed with 80% ice-cold acetone for 30 min in 4°C. To inhibit non-specific 
binding of immunoglobulin, the cultures were incubated in blocking buffer (10% FBS and 1% bovine 
serum albumin (BSA, SERVA) in PBS) at room temperature for 1 h. After rinsing with wash buffer 
(0.05% Tween-20 in PBS), three monoclonal antibodies (MA) were chosen and applied as primary 
antibody: MA anti- βIII-tubulin isoform (Chemicon, 1:500 dilution), MA anti-microtubule associated 
protein 2 (MAP2) (Chemicon, 1:500 dilution), and MA anti-glial fibrillary acidic protein (GFAP) 
(Chemicon, 1:800 dilution). The primary antibody was applied overnight at 4˚C at the given dilution in 
blocking buffer (50 µL/well). Then, after rinsing with wash buffer, the biotin conjugated anti-mouse 
secondary antibody (Chemicon, 1:200 dilution) was applied for 2 h (room temperature, 50 µL/well). 
The cells were then rinsed as above and incubated with streptavidin - FITC (Chemicon) or 
strepatividin - horseradish peroxidase (Chemicon) conjugate (50 μL/well) for 1 h at room temperature. 
IF staining fluorescence was examined using a fluorescent microscope (λ = 490 nm). In IE staining, a 
substrate (3,3’,5,5’-tetramethylbenzidine, SIGMA) was added (100  µL/well) and reaction was 
evaluated for 30 min at room temperature. By adding of 100 ∝Λ 0.5 M sulfuric acid per well the 
reaction was stopped. The expression level of particular proteins was determined by measuring optical 
density at 450 nm. 
 
2.6. Statistical analysis  
 
The values of drug concentration, which inhibited cells viability by 50% (IC50) and reduced 
differentiation by 50% (ID50) when compared to unexposed control cells, were calculated according to 
Hill’s equation (sigmoidal model of concentration-response curve). Statistically significant differences 
between mean values obtained in immunoenzymatic analysis were determined based on analysis of 
variance (ANOVA) followed by Tukey – Kramer post-hoc test. Values of P < 0.05 were considered as 
statistically significant. All calculations were done using LSW Data Analysis Toolbox ver. 1.1.1. Int. J. Mol. Sci. 2009, 10                 
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(MDL® Information Systems, Inc.) in Microsoft Excel 2000 spreadsheet and Kyplot software (Koichi 
Yoshioka, version 2.0 beta 4). In order to classify embryotoxic potential the mean inhibition 
concentrations for differentiation (ID50) of test chemical was used and the biostatistically based 
prediction model (PM) was applied [24]. It is based on the linear discriminate analysis of three 
functions: function I: 6.65  ×  log  (ID50)-9.49;  function  II:  6.16 × log (ID50)-8.29; function III: -
1.31 × log (ID50)-1.42. The function providing the highest value was used to determine the class of 
embryotoxicity (class 1 – non-embryotoxic, class 2 – weakly embryotoxic, class 3   
– strongly embryotoxic). 
 
3. Results 
 
To ensure that our data meet all the acceptance criteria concomitant control cultures were carried 
out. We have ascertained that the medium culture values concerning cells viability and differentiation 
in this study corresponded well with the historical (cumulative) data obtained during in-house 
validation study of this method [25]. Immunofluorescent analysis revealed that control neurospheres 
(Figure 1) contain neurons in early (A) and late (B) stage of development as well as astrocytes (C).  
 
Figure 1. Photomicrographs showing control neurospheres stained using FITC- conjugated 
antibody against βIII tubulin, MAP2 and GFAP. 
 
   
A              βIII tubulin  B                 MAP2  C               GFAP 
 
The intensity of immunostaining was as follow: βIII-tubulin> MAP2>GFAP. Immunoenzymatic 
analysis, showed that the most numerous were neurons in early stage of development (Table 1).  Then, 
the model used was checked by assessment of culture response to reference compounds recommended 
by the European Centre for Validation of Alternative Methods (ECVAM) - 5-fluorouracil (5-FU) and 
penicillin G (Pen-G). Both, 5-FU and Pen-G were classified to the same classes (respectively class 3 – 
strong teratogens and class 1 – non-teratogens) as with use of the scientifically validated tests [24]. 
Pen-G was not embryotoxic at the concentration of 500 µg/mL. The mean values of cytotoxic (IC50) 
and embryotoxic (ID50) concentrations (± standard deviation, SD) for 5-FU are displayed in Table 1.  
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Table 1. Effects of 5-fluorouracil (5-FU) and ochratoxin A (OTA) on viability (NRU test) 
and differentiation (based on six endpoints). 
Endpoint 
Viability Differentiation 
Neutral Red 
OD, 540 nm 
 
Computerised image analysis of 
haematoxylin stained neurospheres 
 
Expression of proteins (OD, 450 nm) 
 
Number 
Total area 
mm
2 
Particular 
area 
mm
2 
 
βIII tubulin 
 
MAP2 GFAP 
Controls  
mean±SD, 
n- number of 
wells 
1.454±0.2084 
n =232 
61±36 
n = 435 
2.56±1.13 
n = 435 
 
0.112±0.059
n = 484 
 
2.592±0.529* 
n = 141 
1.923±0.440* 
n = 207 
1.689±0.405* 
n = 119 
 
Cytotoxicity 
IC50 
Inhibition of differentiation, ID50 
5-FU** 
 
0.15±0.010 0.17±0.016  0.16±0.010 0.21±0.015  0.14±0.010  0.16±0.010 
 
0.18±0.012 
 
IC50/ID50 ratio  0.9  0.9  0.7  1.2  0.9  0.8 
OTA** 2.52±0.062 
 
3.40±1.100 
 
2.19±0.245 1.29±0.923 4.84±0.581  3.90±0.350 
 
4.87±0.351 
 
IC50/ ID50 ratio  0.7  1.1  1.9  0.5  0.6  0.5 
*P<0.05, significant difference was calculated for each pair of means in Tukey–Kramer test  
** µg/mL, mean±SD - from 3 independent experiments 
 
Cultures exposed to ochratoxin A showed dose–dependent reduction in total living cells number 
and differentiation (Figure 2). The mean cytotoxic concentration (IC50) calculated from three 
independent experiments was 2.52 ± 0.062 µg/mL. The mean inhibition concentration for 
differentiation (ID50) was also very low for all endpoints measured (Table 1). When prediction model 
was applied, OTA was classified as a strong teratogen (class 3). Small differences observed were 
depended on the criteria of evaluation. 
Immunoenzymatic assessment of characteristic protein expression level did not show any 
significant differences in the sensitivity of particular embryonic nerve cells to toxic activity of OTA. Int. J. Mol. Sci. 2009, 10                 
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The values of ID50 were 3.90 ± 0.350 μg/mL, 4.84 ± 0.581 μg/mL and 4.87 ± 0.351 μg/mL for MAP2, 
βIII tubulin and GFAP, respectively. IC50/ID50 ratio was similar for all three endpoints, i.e. 0.5 for βIII 
tubulin and GFAP, 0.6 for MAP2 (Table 1).   
Morphometric analysis of haematoxylin stained cultures revealed that the concentrations of OTA 
ranged from 0.63 to 2.5 µg/mL led to the decrease in the particular area and increase in the number of 
neurospheres (Figures 2B, Figure 3). This is probably reflecting a decreased intercellular adhesion 
Concentration response curve for total area was very similar to the illustrating the cytotoxicity (Figure 
2B) , so the IC50/ID50 ratio was 1.1 (Table 1).  
 
Figure 2. Representative concentration-response curves illustrating an effect of ochratoxin 
A on cytotoxicity (NRU test) and differentiation (six different endpoints) in micromass 
embryo midbrain cells cultured in vitro. The cytotoxic concentration of 2.5 µg/mL, 
mentioned in Table 1, resulted in increasing the number of neurospheres and decreasing of 
their area (B). 
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Figure 3.  Images of midbrain micromass cultures, exposed for 5 days to different 
concentrations of OTA. Neurospheres were stained with haematoxylin (16 × 
magnification). After exposure to 2.5 µg/mL neurospheres were smaller and more 
numerous, after two highest concentrations no differentiated cells were observed.  
  
Control  0.16 μg/mL 
  
0.31 μg/mL  0.63 μg/mL 
  
1.25 μg/mL  2.5 μg/mL 
  
5 μg/mL  10 μg/mL 
4. Discussion  
 
Nowadays, there is a trend towards toxicity testing with the use of short test systems in vitro. As 
concerning developmental neurotoxicity (DNT) different alternatives are used [19 - 22]. One of the 
neural cell-based model is the micromass test. The use of micromass cultures of cells derived from rat 
embryonic limb buds and midbrains has been developed and extensively characterised in the 
laboratory of Flint [26, 27], and then applied as in vitro teratogen assay [23, 28 - 30].  Int. J. Mol. Sci. 2009, 10                 
 
 
45
When cells isolated from midbrain of developing embryos are cultured at high density, many of the 
events (movement, communication, division and differentiation), which are most critical to 
embryogenesis, occur so this model, at least in part, resembles in vivo development. In principle, the 
micromass assay is based on detecting the ability of a particular chemical to inhibit the differentiation; 
two endpoint values are usually determined: ID50 for cell differentiation and IC50 for cell 
viability/growth.  
Various approaches have been suggested to identify and characterise developmental toxicity from 
micromass assay. Most often teratogenic potential of a compound was based on the comparison of IC50 
for cell differentiation and cytotoxicity [26, 31, 32]. According to this criterion, the compound is 
assumed as potentially teratogenic if it inhibits the differentiation at non-cytotoxic concentrations 
(IC50/ ID50 ratio>2). The functioning opinion is that the best results (concordance with in vivo studies 
and/or observations on human) are received when combination of two values (high IC50-P/ IC50-D ratio 
and very low IC50-D) is applied. Recently, Walmod et al. [33] hypothesised that a compound is likely 
to be a teratogen if it affects the proliferation or cell morphology, and that an effect on both endpoints, 
rather than just one of them, increases this probability. According to the authors, the concept of 
combining several endpoints in a single evaluation is well known and used. 
In this study, OTA inhibited both viability and differentiation in a concentration – dependent 
manner. The mean inhibition concentrations of cell differentiation were closed to cytotoxic one 
(IC50/ID50 ratio <2). These findings are similar to those reported by Hong et al. [34] in rat embryonic 
limb bud and midbrain micromass cultures, and by Sava et al. [ 35] in adult hipocampal neural 
stem/progenitor cells in vitro. These results allow to conclude that harmful effects of OTA are related 
to the overt cytotoxicity [7, 36]. On the other hand it is known that cytotoxicity and specific toxicities 
are both underlying time kinetics so it is likely that harmful effects on differentiation could be see at an 
earlier timepoint during incubation. 
Analysis of other in vitro data confirmed that cytotoxic potency of ochratoxin A is very high in 
different culture systems indicating that ochratoxin A did not have cell specific effects [37].  OTA has 
been suggested by various researchers to mediate its toxic effects via induction of apoptosis, disruption 
of mitochondrial respiration, inhibition of protein synthesis, oxidative stress, and generation of DNA 
adducts [38-41]. From our study a decreased intercellular adhesion was concluded resulting in 
inhibitory effects on aggregate formation. . 
As the development of the CNS is very complex, much effort should be done to improve in vitro 
cultures and to make the assessment of differentiation more objective [42, 43]. Embryonal CNS cells 
can proliferate in culture, generating aggregates called “neurospheres”. Cells in neurospheres express 
protein, among others βIII tubulin, MAP2, and GFAP, which were used as markers of neurons at early 
and late stage of development and astrocytes, respectively.  
One possible mechanism of neuroteratogenicity is a target toxicity. Belmadani et al. [44] described 
cytotoxic potential of OTA (IC50) for protein and DNA synthesis in the culture of cells isolated from 
different part of rat embryo brain aged of 15-16 days. Median inhibition concentrations  for neurons 
and astrocytes  ventral mesencephalon were approximately 14 ± 2 µM  (5.6 ± 0.40 µg/mL) and 40 ± 5 
µM (16.2 ± 2.15 µg/mL) compared to the cerebellum values 24 ± 7 µM (9.7 ± 2.8 µg/mL ) and 69 ± 9 
µM (27.9 ± 3.6 µg/mL). The same authors, in in vivo studies, designed the ventral mesencephalon, 
hippocampus, striatum, and cerebellum as the main OTA-targets in the brain of adult rats [45]. The Int. J. Mol. Sci. 2009, 10                 
 
 
46
regional selectivity of OTA was investigated in primary cultures of neurons and astrocytes isolated 
from embryonic or newborn rat brain ventral mesencephalon and cerebellum. The cultures were 
exposed to ochratoxin A in a medium containing 10% of foetal calf serum for 46 h. Neuronal cells 
were more sensitive than astrocytes, and the cells of the ventral mesencephalon were more sensitive 
than those of the cerebellum [46]. Zurich et al. [47] found out that OTA-induced alterations were more 
pronounced in cultures at an advanced stage of maturation because OTA may  severely affect the 
neuroprotective capacity of glial cells (inhibition of glial fibrillary acidic protein). It seems to be that 
the differences mentioned above resulted from different experimental conditions, which may suggest 
that OTA toxicity is age and brain region depended. The risk for human health depends on   
many factors. 
 
5. Conclusions 
 
Overall, our results demonstrates that OTA is a strong teratogen (ID50 < 10 µg/mL) and its primary 
harmful effect is general cytotoxicity (similar IC50 and ID50). Immunoenzymatic assessment did not 
show selective toxicity of OTA to particular neurons and astrocytes. Morphometric assessment using 
computer image analysis revealed that teratogenic potency of OTA was correlated with their effects on 
aggregation of neuronal cells and formation of neurospheres. Taken together, the use of different 
endpoints for evaluation of differentiation may offer an interesting improvement of the CNS micromas 
test which might be used, also, for mechanistic studies. 
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